Przejdź do zawartości
Merck

KDR receptor: a key marker defining hematopoietic stem cells.

Science (New York, N.Y.) (1999-09-08)
B L Ziegler, M Valtieri, G A Porada, R De Maria, R Müller, B Masella, M Gabbianelli, I Casella, E Pelosi, T Bock, E D Zanjani, C Peschle
ABSTRAKT

Studies on pluripotent hematopoietic stem cells (HSCs) have been hindered by lack of a positive marker, comparable to the CD34 marker of hematopoietic progenitor cells (HPCs). In human postnatal hematopoietic tissues, 0.1 to 0.5% of CD34(+) cells expressed vascular endothelial growth factor receptor 2 (VEGFR2, also known as KDR). Pluripotent HSCs were restricted to the CD34+KDR+ cell fraction. Conversely, lineage-committed HPCs were in the CD34+KDR- subset. On the basis of limiting dilution analysis, the HSC frequency in the CD34+KDR+ fraction was 20 percent in bone marrow (BM) by mouse xenograft assay and 25 to 42 percent in BM, peripheral blood, and cord blood by 12-week long-term culture (LTC) assay. The latter values rose to 53 to 63 percent in LTC supplemented with VEGF and to greater than 95 percent for the cell subfraction resistant to growth factor starvation. Thus, KDR is a positive functional marker defining stem cells and distinguishing them from progenitors.

MATERIAŁY
Numer produktu
Marka
Opis produktu

Sigma-Aldrich
VEGF Receptor-2 (Flk-1, KDR)/Fc Chimera human, >90% (SDS-PAGE), recombinant, expressed in NSO cells, lyophilized powder